Key result
Anti-TNF therapy such as infliximab may offer therapeutic benefit for carefully selected patients with refractory coeliac disease.
Why the study?
Does infliximab improve outcomes in patients with refractory coeliac disease?
Does infliximab improve outcomes in patients with refractory coeliac disease?
Anti-TNF therapy such as infliximab may be beneficial for carefully selected patients with refractory coeliac disease.
May support targeted use in refractory coeliac disease; leaves open need for randomized confirmation.
Coeliac disease is generally well controlled with gluten-free diet but a small proportion of patients require corticosteroids or immunomodulatory agents. Response to anti-tumour necrosis factor (anti-TNF) agents raises interesting questions about both the pathogenesis of coeliac disease and the mechanism of action of anti-TNF agents. Refractory coeliac disease poses a therapeutic challenge to clinicians and carefully selected patients may benefit from anti-TNF therapy.
No takes yet. Share an insight, caveat, or question.
Subrata Ghosh (2005) conducted a review in Refractory coeliac disease. Infliximab (anti-TNF therapy) was evaluated. Anti-TNF therapy such as infliximab may offer therapeutic benefit for carefully selected patients with refractory coeliac disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: